<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02135705</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-025</org_study_id>
    <nct_id>NCT02135705</nct_id>
  </id_info>
  <brief_title>LOWER: Lomitapide Observational Worldwide Evaluation Registry</brief_title>
  <acronym>LOWER</acronym>
  <official_title>LOWER: Lomitapide Observational Worldwide Evaluation Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This global product exposure registry is a multicentre, long-term, prospective,
      observational cohort study (exposure registry), designed to evaluate the long term safety
      and effectiveness of lomitapide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the occurrence of adverse events of special interest, long term effectiveness of
      lomitapide, and to evaluate whether prescribers of lomitapide are following screening and
      monitoring recommendations as specified in product labeling.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Hepatic Abnormalities</measure>
    <time_frame>patients will be followed for 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate the occurrence of hepatic abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal (GI) Events</measure>
    <time_frame>patients will be followed for 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate the occurrence of GI events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumors</measure>
    <time_frame>patients will be followed for 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate any occurrence of tumors (small bowel, hepatic, colorectal or pancreatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events associated with coagulopathy</measure>
    <time_frame>patients will be followed for 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate the occurrence of events associated with coagulopathy (abnormal bleeding, cerebral haemorrhage or GI bleeding)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Lomitapide</arm_group_label>
    <description>Lomitapide as prescribed by Physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomitapide</intervention_name>
    <description>As prescribed by Physician.</description>
    <arm_group_label>Lomitapide</arm_group_label>
    <other_name>Juxtapid</other_name>
    <other_name>Lojuxta</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients treated with lomitapide who agree to participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age â‰¥18 years) who meet one of the following two criteria:

        Initiating treatment with lomitapide at the time of registry enrolment, or initiated
        treatment with lomitapide within 15 months prior to enrolment into the registry and after
        lomitapide commercial availability in the country.

          -  Patients who have the ability to understand the requirements of the study   and
             provide written informed consent to comply with the study data collection procedures.

        Exclusion Criteria:

          -  Patients who are receiving lomitapide in clinical trials

          -  Patients receiving an investigational agent, defined as any drug or biologic agent
             other than lomitapide that has not received MA in the country of participation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aegerion Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complete Family Care</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
